Harbour BioMed (HBM) announced the appointment of Dr. Jon Wigginton M.D., to the company's scientific advisory board (SAB). Dr. Wigginton is a physician-scientist and leader in immuno-oncology drug development with more than 20 years in senior roles at the U.S, National Institutes of Health, Bristol-Myers Squibb, Merck, MacroGenics, and Cullinan Oncology, where he is Chief Medical Officer.
"Dr. Wigginton is a seasoned scientific leader whose expertise spans basic scientific research, translational medicine and clinical development," said Dr. Jingsong Wang, M.D., Ph,D., Founder, Chairman and CEO of Harbour BioMed. "We are very excited to have Dr. Wigginton join our SAB team and look forward to his guidance in accelerating our programs to develop the next generation of immuno-oncology therapeutics."
"HBM has an exciting portfolio and its research stands at the cutting edge of scientific progress that is being conducted to bring next generation immuno-therapeutics to address unmet medical needs." said Dr. Wigginton: "I look forward to working with Jingsong and his team."
Dr. Wigginton recently joined Cullinan Oncology, where he serves as Chief Medical Officer, and leads clinical development for Cullinan's portfolio companies. He also serves as an Advisor at MPM Capital, where he provides input on potential oncology investments and clinical development plans for portfolio companies. Previously, Dr. Wigginton served as Chief Medical Officer and Senior Vice-President, Clinical Development at MacroGenics.
Previously, Dr. Wigginton served as Therapeutic Area Head, Immuno-Oncology Early Clinical Research at Bristol-Myers Squibb. At BMS, he oversaw the early clinical development of the Company's Immuno-Oncology portfolio, from first-in-man through proof-of-concept, co-led the BMS International Immuno-Oncology Network, and served in a governance role for immuno-oncology discovery. These efforts led to demonstration of proof-of-concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with a range of different cancers, and for the anti-PD-1/anti-CTLA-4 combination in melanoma.
Dr. Wigginton also had a lengthy career at the National Cancer Institute, serving as Head of the Investigational Biologics Section in the Center for Cancer Research, where he led an integrated basic, translational, and clinical research effort focused on combination immunotherapy. Dr. Wigginton's work has been recognized through numerous peer-reviewed publications, abstracts, and invited presentations at various national and international scientific programs, and he previously served as President of the Society for Immunotherapy of Cancer (SITC).
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Severity: Warning
Message: count(): Parameter must be an array or an object that implements Countable
Filename: amp/news_details_amp.php
Line Number: 252
Backtrace:
File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler
File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view
File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.
media@smartmarketnews.com | sales@smartmarketnews.com
Contact Us